TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. meeting Rome Ⅲ criteria for diagnosing functional constipation;~2. severe chronic constipation (two or fewer CSBMs per week for more than 3 months）;~3. the weekly mean CSBMs are no more than 2 times during the 2-week baseline~4. aged from 18 to 75 years old~5. no use of drugs for constipation (emergency treatments should be excepted) during at least 2 weeks before enrollment; no acupuncture treatment for constipation in the previous 1 month; never joined any other trial in progress;~6. volunteered to join this research and signed the informed consent~Exclusion Criteria:~1. irritable bowel syndrome, organic constipation or secondary constipation caused by endocrine, metabolic, nervous, postoperative diseases, or by drugs;~2. mushy stool or watery stool are showed more than once during baseline when defecating spontaneously without any laxative (Bristol stool type 6 or 7);~3. history of pelvic floor dysfunction;~4. taking medicine in progress which can induce constipation;~5. severe hemorrhoid or anal fissure;~6. constipation with serious cardiovascular, hepatic or renal diseases, cognitive dysfunction, abdominal aortic aneurysm or hepatosplenomegaly, aphasia, mental disorders, or illness which affects the cooperation for examination and treatment;~7. women in gestation or lactation period;~8. blood coagulation disorders or using anticoagulants regularly such as Warfarin and Heparin;~9. cardiac pacemaker carrier.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Electro-acupuncture (Type: EXPERIMENTAL): Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
- Prucalopride (Type: ACTIVE_COMPARATOR): Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil for IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 70 years~* Renal biopsy showing a histological diagnosis IgAN, with predominant or codominant mesangial deposition of IgA on immunofluorescent studies~* Daily urinary protein excretion \> 1 g on at least 3 separate occasions~* Serum creatinine \< 400 umol/L~* Patients who are willing to give written informed consent and to participate in and comply with the study protocol~Exclusion Criteria:~* Presence of concomitant glomerular diseases~* Patients with known hypersensitivity to MMF~* Patients receiving treatment with other cytotoxic agents~* Serum creatinine \> 400 umol/L~* Women who are lactating, pregnant or of childbearing potential not using, or who are unwilling to use, a reliable contraceptive method during and for 6 weeks following conclusion of MMF therapy. A pregnancy test to exclude pregnancy will be performed for women of childbearing potential prior to recruitment~* Patients who are unable or unwilling to give written informed consent and to participate in and comply with the study protocol~* Presence of systemic infection or malignancy requiring therapy at the time of entry to the study~* Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MMF
- 2 (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Has completed the Week 12/End-of-treatment visit of the antecedent study, Study ACP-2566-003~2. Met all entry criteria for the antecedent study~3. May benefit from long-term treatment with open-label trofinetide in the judgment of the Investigator~4. Can still swallow the study medication provided as a liquid solution or can take it by gastrostomy tube~5. The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments~6. Subject and caregiver(s) must reside at a location to which study drug can be delivered and have been at their present residence for at least 3 months prior to Baseline~Exclusion Criteria:~1. Began treatment with growth hormone during the antecedent study~2. Began treatment with IGF-1 during the antecedent study~3. Began treatment with insulin during the antecedent study~4. Has developed a clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study~5. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study~6. Has a clinically significant abnormality in vital signs at Baseline~7. Has a QTcF interval of \>450 ms on the Baseline ECG performed before the first dose of trofinetide is given in the present study~8. Has developed a clinically significant ECG finding during the antecedent study~Additional inclusion/exclusion criteria apply. Patients will be evaluated at baseline to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all prespecified entry criteria).

- Gender: FEMALE
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Trofinetide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Study of KW-3357

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the ACCP/SCCM-defined sepsis criteria~* Japanese Association for Acute Medicine-defined DIC criteria score \>= 4~* Antithrombin activity \<= 70%~* Written informed consent from patient or guardian~Exclusion Criteria:~* Anamnesis or complication of serious drug allergy~* Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis~* Pregnant, nursing, or possibly pregnant woman

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KW-3357 (Type: EXPERIMENTAL): None
- Plasma-derived antithrombin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* Not on a statin or on a low dose statin with stable dose for at least 4 weeks~* History of intolerance to at least 2 statins~* Subject not at LDL-C goal~* Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks.~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes, poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Ezetimibe (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Evolocumab Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
- Evolocumab QM (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Child Restraint Installation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* communicate in English~* drive a vehicle with one or more car seats present~* willing to install a car seat into the vehicle~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- interactive virtual presence (Type: EXPERIMENTAL): install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness of Osteopathic Manipulative Treatment in Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* aged between 18 and 60 years old~* chronic migraine~Exclusion Criteria:~* secondary forms of headache,~* chronic illness,~* psychiatric illness,~* post-menopausal women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- sham therapy (Type: SHAM_COMPARATOR): subtracting serial sevel (McPartland 2003)
- usual care (Type: OTHER): triptans treatment only
- OMT (Type: EXPERIMENTAL): 8 sessions of osteopathic manipulative treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Western Equine Encephalitis Vaccine, Inactivated

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-55 years of age~* In good health as determined by pertinent medical history, brief physical exam, vital signs, and clinical safety laboratory evaluations~* Female: has a negative urine pregnancy test and is willing to use reliable form of contraception for the study duration~* Negative HIV antibody screen, seronegative for HBsAg and Hepatitis C antibody~* WEE, EEE, VEE, and CHIK PRNT80\<1:10~* Ability to comprehend abnd a willingness to sign an informed consent, which includes the HIPAA and a separate HIV consent form~* Be willing to comply with all follow-up visits, testing, and AE reporting~Exclusion Criteria:~* Participant in the USAMRIID SIP~* Receipt of any other vaccine or investigational; drug within 30 days prior to study entry~* Anticipates receipt of other vaccines for the duration of the study (influenza vaccination will be permitted but not within 28 days of WEE vaccination~* Acute of chronic medical conditions, medications, or dietary supplements that, in the PI's opinion, would impair the subject's ability to respond to vaccination~* Hypersensitivity to any vaccine~* Allergic to any vaccine component: Human serum albumin, Neomycin~* Receipt of or anticipates receipt of blood products during the study~* Female: Pregnant or breastfeeding~* Clinically significant abnormal laboratory tests (generally greater than or equl to 2 times the upper limit of normal as determined by the PI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Vaccinated (Type: EXPERIMENTAL): Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females with CDAD~* Females must use adequate contraception~* Signed informed consent~Exclusion Criteria:~* Life-threatening CDAD~* Toxic megacolon~* Pregnant~* Concurrent use of diarrheal agents~* Participation in other trials

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fidaxomicin (Type: EXPERIMENTAL): Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours \[q12h\] regimen) with intermittent matching placebo to fidaxomicin
- Vancomycin (Type: ACTIVE_COMPARATOR): Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours \[q6h\] regimen).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Riboflavin-Enhanced Hyaluronic Acid Eye Drops in Treating Dry Eye Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for patient selection included a dry eye history of at least three months, OSDI score ≥ 23, and positivity in at least one eye for one or more of the following diagnostic criteria:~* Tear Break-Up Time (TBUT) \< 7 seconds~* Schirmer test I at 5 minutes \< 10 mm~* Corneal and/or conjunctival fluorescein staining~* Tear osmolarity \> 308 mOsm/L or a difference of at least 8 mOsm/L between both eyes.~Exclusion Criteria:~* Age below 18 years~* Severe ocular surface affections~* Unilateral dry eye syndrome~* Refractive surgery performed within the last six months~* Eye surgery performed within the last three months~* Previous herpetic keratitis~* Signs of active corneal infection~* Systemic or topical steroid therapy within the last 30 days~* Topical therapy within the last 14 days~* Inability to understand the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group X: Ribohyal Group (Type: None): Composed of 16 eyes (right or left) assigned for the use of modified hyaluronic acid, HAr® 0.1%, covalently linked to Riboflavin
- Group Y: (Control Group) (Type: None): Composed of 16 eyes (right or left) assigned for the use of HA 0.1% alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18- 80 years of age, both sexes, all races and ethnic groups.~* Diagnosis of restless legs syndrome~* Disease duration longer than 3 months~* Restless Leg Syndrom Rating Scale score of 11 or above (moderate and above)~* Subjects who are eligible to be treated with a botulinum toxin for a therapeutic reason based upon the physicians' clinical experience.~* Subjects who are able to read, speak, and understand English.~Exclusion Criteria:~* Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders).~* Pregnancy or planned pregnancy (determined by urine pregnancy test). Women of childbearing age should use a reliable mode of contraception during the study period (abstinence, etc).~* Active breast feeding.~* Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.~* Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.~* Subjects who are younger than 18 years of age.~* Neuromuscular-junction disorders.~* Evidence of acute pathology by neuro-imaging.~* Axis I diagnosis determined by a neurologist or psychiatrist.~* Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.~* Subject has received botulinum toxin injections in the past 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo , saline (Type: PLACEBO_COMPARATOR): The subject may be randomly assigned to receive Placebo, saline
- IncobotulinumtoxinA Treatment (Type: ACTIVE_COMPARATOR): The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Discussing Stopping Cancer Screening and Prognosis With Older Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English-speaking~* Aged 76 to 89 years~* Scheduled for a routine visit or physical with their PCP in the next 3-12 weeks~* Patient aged 76-79 must have a least one Charlson Comorbidity~* Patient must have undergone CRC screening within the last 10 years~* Women only: patient must have undergone mammography screening within the last 3 years~Exclusion Criteria:~* older adults with dementia~* older adults with a history of colon cancer~* older adults whose last colonoscopy was read as abnormal~* older women who have a history of breast cancer~* older adults whose PCP has already had 5 patients participate in the study~* older women whose last mammogram was read as abnormal

- Gender: ALL
- Minimum Age: 76 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Prognosis Information and Provider Scripts (Type: EXPERIMENTAL): Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete